Alnylam Shares Halted Ahead Of FDA Cardiovascular And Renal Drugs Advisory Committee Meeting On sNDA For Onpattro
Portfolio Pulse from Charles Gross
Shares of Alnylam Pharmaceuticals have been halted ahead of the FDA Cardiovascular and Renal Drugs Advisory Committee meeting on the supplemental New Drug Application (sNDA) for Onpattro.
September 13, 2023 | 10:59 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Alnylam Pharmaceuticals' shares have been halted in anticipation of the FDA's meeting on the sNDA for Onpattro. The outcome of this meeting could significantly impact the company's stock price.
The halt in Alnylam's shares is directly related to the upcoming FDA meeting. The outcome of this meeting, specifically the FDA's decision on the sNDA for Onpattro, could either positively or negatively affect the company's stock price. Therefore, the relevance and importance are high. The score is neutral as the direction of the impact will depend on the FDA's decision.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100